Shots: ViiV Healthcare has reported a regulatory submission to the US FDA for the approval of a new dispersible tablet formulation of the fixed-dose combination of abacavir, dolutegravir & lamivudine. […]readmore
Tags : dolutegravir
Clinical Trials
ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III
Shots: The P-III TANGO study evaluating the antiviral efficacy and safety of dolutegravir/lamivudine switching to a 2DR vs TAF based regimens in HIV-infected adults who had not experienced prior virologic […]readmore
Shots: The approval is based on ongoing P1093 (NCT03016533) and ODYSSEY (PENTA20, NCT02259127) studies in pediatric patients aged 4 weeks to 18 years, while the second study involves 2L pediatric […]readmore
Shots: The company has filed submissions to both EMA and FDA for the approval of the first-ever DT formulation of DTG (5mg) as well as a simplified dosing regimen to […]readmore
Pharma
ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives European Commission Marketing Authorization for
Shots: The marketing authorization is based on GEMINI 1 & 2 studies result assessing Dovato vs dolutegravir + tenofovir disoproxil fumarate/emtricitabine in 1400+ patients with HIV-1 infection for 48wks. The […]readmore